Sulfonamide inhibitors of matrix metalloproteinases

A method of inhibiting a matrix metalloproteinase, the method comprising administering to a patient in need of matrix metalloproteinase inhibition a matrix metalloproteinase inhibiting amount of a compound of Formula I

• wherein:
• Ar is selected from phenyl;
• phenyl substituted with alkyl, —NO2, halogen, —OR5, —CN, —CO2R5, —SO3R5, —CHO, —COR5, —CONHR5, —NHR5, or —NHCOR5;
• heteroaryl;
• or
• 2-naphthyl;
• R1 is hydrogen, methyl, —NO2, —Cl, —NH2, —NHCO2CH3, —OH, or —CO2H;
• R2 and R3 are the same or different and are independently selected from hydrogen, alkyl, —(CH2)v-aryl, —(CH2)v-heteroaryl, —(CH2)v-cycloalkyl, —(CH2)p—X—(CH2)q-aryl, —(CH2)p—X—(CH2)q-heteroaryl, —(CH2)t—NR6R6a, —(CH2)v—R7, —(CH2)v—CO2R5, —(CH2)v—CONR6R6a, or —(CH2)v—SR5;
• m is zero or 1;
• Y is CH;
• z is zero or 1;
• W is —CHR8;
• n is zero or 1;
• R4 is —OH, —NR6R6a, or —NHOR9;
• R5 is hydrogen or alkyl;
• v is 1 to 5;
• X is O or S;
• p and q are independently 1 to 5, provided that p+q is not greater than 5;
• t is 1 to 9;
• R6 and R6a are each the same or different and are hydrogen or alkyl;
• R7 is 1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl, or 1,3-dihydro-1,3-dioxo-benzo[f]isoindol-2-yl;
• R8 is hydrogen or alkyl;
• R9 is hydrogen, alkyl, or benzyl;
• or
• a pharmaceutically acceptable salt thereof.